AstraZeneca Pharma India Limited

NSEI:ASTRAZEN 株式レポート

時価総額:₹162.4b

AstraZeneca Pharma India 将来の成長

Future 基準チェック /06

現在、 AstraZeneca Pharma Indiaの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長17.9%
収益成長率n/a
将来の株主資本利益率n/a
アナリストカバレッジ

None

最終更新日n/a

今後の成長に関する最新情報

更新なし

Recent updates

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

Sep 18
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06
AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25
Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18
Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13
We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25
Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07
Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20
What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28
If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02
What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、AstraZeneca Pharma India は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NSEI:ASTRAZEN - アナリストの将来予測と過去の財務データ ( )INR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
9/30/202414,84581983169N/A
6/30/202413,876959N/AN/AN/A
3/31/202412,9551,615171279N/A
12/31/202311,9701,393N/AN/AN/A
9/30/202311,4101,528639714N/A
6/30/202310,6611,330N/AN/AN/A
3/31/202310,030993498583N/A
12/31/20229,5021,100N/AN/AN/A
9/30/20229,009921776856N/A
6/30/20228,625715N/AN/AN/A
3/31/20228,0566169121,008N/A
12/31/20217,839609N/AN/AN/A
9/30/20217,8367051,4421,550N/A
6/30/20217,954849N/AN/AN/A
3/31/20218,1369339711,048N/A
12/31/20207,982756N/AN/AN/A
9/30/20208,218813154228N/A
6/30/20208,208693N/AN/AN/A
3/31/20208,318722732874N/A
12/31/20198,272725N/AN/AN/A
9/30/20198,185749358564N/A
6/30/20197,714696N/AN/AN/A
3/31/20197,283545363550N/A
12/31/20186,887478N/AN/AN/A
9/30/20186,02183N/AN/AN/A
6/30/20186,050265N/AN/AN/A
3/31/20185,710259N/A88N/A
12/31/20175,319175N/AN/AN/A
9/30/20175,536442N/AN/AN/A
6/30/20175,275176N/AN/AN/A
3/31/20175,437201N/A381N/A
12/31/20165,866279N/AN/AN/A
9/30/20165,809206N/AN/AN/A
6/30/20165,711131N/AN/AN/A
3/31/20165,63753N/A570N/A
12/31/20155,529428N/AN/AN/A
9/30/20155,166207N/AN/AN/A
6/30/20154,753-5N/AN/AN/A
3/31/20154,690-208N/A-457N/A
12/31/20144,624-615N/AN/AN/A
9/30/20144,732-466N/AN/AN/A
6/30/20144,742-199N/AN/AN/A
3/31/20144,737-5N/A-8N/A
12/31/20134,545-165N/AN/AN/A

アナリストによる今後の成長予測

収入対貯蓄率: ASTRAZENの予測収益成長が 貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ASTRAZENの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ASTRAZENの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ASTRAZENの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ASTRAZENの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: ASTRAZENの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘